IFN-β also alleviates MS by upregulating PD-L1 on semi-mature DCs and inhibiting the activation of CD4+ T cells, which maintains peripheral immune tolerance (Schreiner et al., 2004). Here, IFNB1 is linked to myeloid sarcoma.